{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:54:57Z","timestamp":1791248097988,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.2515\/therapie\/2010031","type":"journal-article","created":{"date-parts":[[2010,8,10]],"date-time":"2010-08-10T13:51:23Z","timestamp":1281448283000},"page":"187-193","source":"Crossref","is-referenced-by-count":10,"title":["Suivi th\u00e9rapeutique pharmacologique des 6-thioguanine nucl\u00e9otides dans les leuc\u00e9mies aigues lymphoblastiques de l\u2019enfant : int\u00e9r\u00eat et limites"],"prefix":"10.1016","volume":"65","author":[{"given":"May","family":"Fakhoury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Jacqz-Aigrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiphaine","family":"de Beaumais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"M\u00e9dard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.2515\/therapie\/2010031_bb0005","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1067\/mps.2002.121790","article-title":"Acute lymphoblastic leukemia","volume":"32","author":"Chan","year":"2002","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"10.2515\/therapie\/2010031_bb0010","first-page":"31","article-title":"Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia","volume":"29","author":"Rubnitz","year":"2003","journal-title":"Cancer Treat Res"},{"key":"10.2515\/therapie\/2010031_bb0015","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1053\/beha.2002.0226","article-title":"New treatment strategies in childhood acute lymphoblastic leukaemia","volume":"15","author":"Schrappe","year":"2002","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.2515\/therapie\/2010031_bb0020","first-page":"14","article-title":"Progr\u00e8s dans le traitement des h\u00e9mopathies malignes et cancers de l\u2019enfant","volume":"119","author":"Cornu","year":"2000","journal-title":"Louvain Med"},{"key":"10.2515\/therapie\/2010031_bb0025","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N Eng J Med"},{"key":"10.2515\/therapie\/2010031_bb0030","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010031_bb0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1126\/science.2649979","article-title":"The purine path to chemotherapy","volume":"244","author":"Elion","year":"1989","journal-title":"Science"},{"key":"10.2515\/therapie\/2010031_bb0040","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0022-3476(05)83063-X","article-title":"Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferasedeficient child with acute lymphocytic leukemia","volume":"119","author":"Evans","year":"1991","journal-title":"J Pediatr"},{"key":"10.2515\/therapie\/2010031_bb0045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/clpt.1989.119","article-title":"Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism","volume":"46","author":"Lennard","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"10.2515\/therapie\/2010031_bb0050","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/0140-6736(93)93028-Y","article-title":"Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient","volume":"341","author":"Sch\u00fctz","year":"1993","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010031_bb0055","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0140-6736(90)91745-V","article-title":"RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia","volume":"336","author":"Lennard","year":"1990","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010031_bb0060","doi-asserted-by":"crossref","first-page":"608","DOI":"10.7326\/0003-4819-126-8-199704150-00003","article-title":"Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance","volume":"126","author":"Yates","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.2515\/therapie\/2010031_bb0065","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/hmg\/8.2.371","article-title":"Polymorphism of the thiopurine-Smethyltransferase gene in African- Americans","volume":"8","author":"Hon","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.2515\/therapie\/2010031_bb0070","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/sj.leu.2401723","article-title":"Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia","volume":"14","author":"McLeod","year":"2000","journal-title":"Leukemia"},{"key":"10.2515\/therapie\/2010031_bb0075","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.bcp.2004.10.011","article-title":"Identification and functional analysis of two rare allelic variants of the thiopurine S-methyltransferase gene, TPMT*16 and TPMT*19","volume":"69","author":"Hamdan-Khalil","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.2515\/therapie\/2010031_bb0080","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1365-2125.2009.03439.x","article-title":"Characterization of a novel TPMT mutation associated with azathioprine-induced myelosuppression","volume":"68","author":"de Beaumais","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2010031_bb0085","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1073\/pnas.92.4.949","article-title":"A single point mutation leading to loss of catalylic activity in human thiopurine S-methyltransferase","volume":"92","author":"Krynetski","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.2515\/therapie\/2010031_bb0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/dna.1996.15.17","article-title":"Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism","volume":"15","author":"Szumlanski","year":"1996","journal-title":"DNA Cell Biol"},{"key":"10.2515\/therapie\/2010031_bb0095","doi-asserted-by":"crossref","first-page":"6444","DOI":"10.1073\/pnas.94.12.6444","article-title":"Enhanced proteolysis of thiopurine-S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity","volume":"94","author":"Tai","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.2515\/therapie\/2010031_bb0100","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/01213011-199910000-00011","article-title":"Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C","volume":"9","author":"Tai","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.2515\/therapie\/2010031_bb0105","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.bjp.0702152","article-title":"Genotypic and phenotypic analysis of the polymorphic thiopurine S- methyltransferase gene (TPMT) in a European population","volume":"125","author":"Spire-Vayron de la Moureyre","year":"1998","journal-title":"British Journal of Pharmacology"},{"key":"10.2515\/therapie\/2010031_bb0110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00008571-199902000-00006","article-title":"The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations","volume":"9","author":"Collie-Duguid","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.2515\/therapie\/2010031_bb0115","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/hmg\/8.2.367","article-title":"Thiopurine methyltransferase alleles in British and Ghanaian populations","volume":"8","author":"Ameyaw","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.2515\/therapie\/2010031_bb0120","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1046\/j.1365-2141.1999.01416.x","article-title":"Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia","volume":"105","author":"McLeod","year":"1999","journal-title":"British Journal of Haematology"},{"key":"10.2515\/therapie\/2010031_bb0125","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0009-9236(97)90152-1","article-title":"Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms","volume":"62","author":"Otterness","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.2515\/therapie\/2010031_bb0130","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1200\/JCO.2001.19.8.2293","article-title":"Preponderance of thiopurine Smethyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine","volume":"19","author":"Evans","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.2515\/therapie\/2010031_bb0135","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s002280050095","article-title":"Intraindividual variability in red blood cell thiopurine methyltransferase activity","volume":"50","author":"Giverhaug","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"10.2515\/therapie\/2010031_bb0140","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/00007890-199205000-00016","article-title":"The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients","volume":"53","author":"Chocair","year":"1992","journal-title":"Transplantation"},{"key":"10.2515\/therapie\/2010031_bb0145","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00008571-199510000-00003","article-title":"Higher activity of polymorphic thiopurine-S-methyltransferase in erythrocytes from neonates compared to adults","volume":"5","author":"McLeod","year":"1995","journal-title":"Pharmacogenetics"},{"key":"10.2515\/therapie\/2010031_bb0150","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1046\/j.0306-5251.2001.01497.x","article-title":"Human thiopurine methyltransferase activity varies with red blood cell age","volume":"52","author":"Lennard","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2010031_bb0155","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2710.2007.00858.x","article-title":"Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with ALL?","volume":"32","author":"Fakhoury","year":"2007","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.2515\/therapie\/2010031_bb0160","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0024-3205(97)01116-8","article-title":"Human thiopurine methyltransferase: no evidence of activation by its substrates","volume":"62","author":"Stupans","year":"1998","journal-title":"Life Sci"},{"key":"10.2515\/therapie\/2010031_bb0165","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/0140-6736(93)93168-Z","article-title":"Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient","volume":"34","author":"McLeod","year":"1993","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010031_bb0170","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood.V93.9.2817","article-title":"Prognostic importance of 6-MP dose intensity in acute lymphoblastic leukemia","volume":"93","author":"Relling","year":"1999","journal-title":"Blood"},{"key":"10.2515\/therapie\/2010031_bb0175","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/35101056","article-title":"Pharmacogenetics and cancer therapy","volume":"1","author":"Relling","year":"2001","journal-title":"Nat rev cancer"},{"key":"10.2515\/therapie\/2010031_bb0180","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2125.2008.03248.x","article-title":"Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine","volume":"66","author":"Hawwa","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2010031_bb0185","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/clpt.2008.154","article-title":"Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia","volume":"85","author":"Stocco","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.2515\/therapie\/2010031_bb0190","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/leu.2008.317","article-title":"Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients","volume":"23","author":"Karas-Kuzclicki","year":"2009","journal-title":"Leukemia"},{"key":"10.2515\/therapie\/2010031_bb0195","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/clpt.1987.4","article-title":"Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations","volume":"41","author":"Lennard","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"10.2515\/therapie\/2010031_bb0200","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2008.316","article-title":"Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study","volume":"23","author":"Schmiegelow","year":"2009","journal-title":"Leukemia"},{"key":"10.2515\/therapie\/2010031_bb0205","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/jnci\/91.23.2001","article-title":"Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-Methyltransferase gene locus","volume":"91","author":"Relling","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.2515\/therapie\/2010031_bb0210","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jama.293.12.1485","article-title":"Thiopurine methyltransfrase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia","volume":"293","author":"Stanulla","year":"2005","journal-title":"JAMA"},{"key":"10.2515\/therapie\/2010031_bb0215","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/FTD.0b013e31818b0f31","article-title":"Thiopurine S-methyltransferase (TPMT) gene polymorphism in Brazilian children with acute lymphoblastic leukemia: association with clinical and laboratory data","volume":"30","author":"Silva","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2010031_bb0220","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1182\/blood-2008-12-193250","article-title":"Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-M\u00fcnster protocols","volume":"114","author":"Stanulla","year":"2009","journal-title":"Blood"},{"key":"10.2515\/therapie\/2010031_bb0225","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1365-2125.2008.03281.x","article-title":"Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia","volume":"66","author":"Hawwa","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2010031_bb0230","first-page":"21","article-title":"M\u00e9thodologie pour l\u2019\u00e9valuation du niveau de preuve du suivi th\u00e9rapeutique pharmacologique","volume":"23","author":"Le Guellec","year":"2009","journal-title":"La Lettre du Pharmacologue"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716306850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716306850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T05:50:42Z","timestamp":1591768242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716306850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0040595716306850"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2010031","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}